These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 17386839)

  • 1. Natriuretic peptides and remodeling in heart failure.
    Burnett JC
    Heart Fail Clin; 2005 Apr; 1(1):129-39. PubMed ID: 17386839
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cardioprotective effects of natriuretic peptides].
    Horio T
    Nihon Rinsho; 2004 Sep; 62 Suppl 9():65-8. PubMed ID: 15506339
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic potential of infused cardiac natriuretic peptides in myocardial infarction.
    Richards AM
    Heart; 2009 Aug; 95(16):1299-300. PubMed ID: 19447834
    [No Abstract]   [Full Text] [Related]  

  • 4. Recommendations for the clinical use of cardiac natriuretic peptides.
    Emdin M; Clerico A; Clemenza F; Galvani M; Latini R; Masson S; Mulè P; Panteghini M; Valle R; Zaninotto M; Ganau A; Mariotti R; Volpe M; Aspromonte N; Cacciatore G; Cappelletti P; L'Abbate A; Miglio F; Ottani F; Pagani F; Passino C; Plebani M; Sarzani R; Zucchelli G; ; ; ; ; ;
    Ital Heart J; 2005 May; 6(5):430-46. PubMed ID: 15934421
    [No Abstract]   [Full Text] [Related]  

  • 5. K(ATP) activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function.
    Gao S; Long CL; Wang RH; Wang H
    Cardiovasc Res; 2009 Aug; 83(3):444-56. PubMed ID: 19304734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurohormonal activation in populations susceptible to heart failure.
    Arnlöv J; Vasan RS
    Heart Fail Clin; 2005 Apr; 1(1):11-23. PubMed ID: 17386830
    [No Abstract]   [Full Text] [Related]  

  • 7. [Natriuretic peptides: anything new in cardiology?].
    Malinowski M; Biernat J; Roleder T; Dalecka AM; Reszka B; Deja MA; Wośf S; Gołba KS
    Kardiol Pol; 2006 Oct; 64(10 Suppl 6):S578-85. PubMed ID: 20527380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do engineered natriuretic peptides have greater therapeutic potential than do native peptides?
    From AH
    Cardiovasc Res; 2010 Dec; 88(3):391-2. PubMed ID: 20935165
    [No Abstract]   [Full Text] [Related]  

  • 9. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases.
    Rubattu S; Sciarretta S; Valenti V; Stanzione R; Volpe M
    Am J Hypertens; 2008 Jul; 21(7):733-41. PubMed ID: 18464748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular and metabolic effects of natriuretic peptides.
    Moro C; Berlan M
    Fundam Clin Pharmacol; 2006 Feb; 20(1):41-9. PubMed ID: 16448393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential for existing and novel forms of natriuretic peptides.
    Chen HH; Burnett JC
    Heart Fail Clin; 2006 Jul; 2(3):365-73. PubMed ID: 17386905
    [No Abstract]   [Full Text] [Related]  

  • 12. Nesiritide: the latest drug for treating heart failure.
    Fontana D
    Crit Care Nurse; 2006 Feb; 26(1):39-44, 46-7. PubMed ID: 16443809
    [No Abstract]   [Full Text] [Related]  

  • 13. Current and novel pharmacological approaches to renal insufficiency in heart failure.
    Hindnavis V; Tang WH
    Minerva Cardioangiol; 2006 Dec; 54(6):753-62. PubMed ID: 17167387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic therapy for acute heart failure.
    Tang WH
    Cardiol Clin; 2007 Nov; 25(4):539-51; vi. PubMed ID: 18063158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New pharmacologic therapies for acute heart failure.
    Tavares M; Rezlan E; Vostroknoutova I; Khouadja H; Mebazaa A
    Crit Care Med; 2008 Jan; 36(1 Suppl):S112-20. PubMed ID: 18158470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of arresting the process of remodeling.
    Somasundaram PE; Chandrashekhar Y
    Med Clin North Am; 2004 Sep; 88(5):1193-207, x. PubMed ID: 15331313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased myocardial chromogranin a expression and colocalization with brain natriuretic peptide during reverse cardiac remodeling after ventricular unloading.
    Wohlschlaeger J; von Winterfeld M; Milting H; El Banayosy A; Schmitz KJ; Takeda A; Takeda N; Azhari P; Schmid C; August C; Schmid KW; Baba HA
    J Heart Lung Transplant; 2008 Apr; 27(4):442-9. PubMed ID: 18374882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natriuretic peptides: novel therapeutic targets in heart failure.
    Cataliotti A; Burnett JC
    J Investig Med; 2005 Nov; 53(7):378-84. PubMed ID: 16297366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with cardiorenal anemia syndrome.
    Leszek P; Kruszewski M
    Am Heart J; 2008 Mar; 155(3):e25; author reply e19. PubMed ID: 18294469
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of long-term B-type natriuretic peptide treatment on left ventricular remodeling and function after myocardial infarction in rats.
    He J; Chen Y; Huang Y; Yao F; Wu Z; Chen S; Wang L; Xiao P; Dai G; Meng R; Zhang C; Tang L; Huang Y; Li Z
    Eur J Pharmacol; 2009 Jan; 602(1):132-7. PubMed ID: 19027731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.